Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study

Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with statistically significant improvements in overall...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	MDPI AG 2023-06-01
Sraith:	Current Oncology
Ábhair:	metastatic colorectal cancer regorafenib trifluridine/tipiracil third-line therapy real-world study
Rochtain ar líne:	https://www.mdpi.com/1718-7729/30/6/413
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!